🇺🇸 FDA
Pipeline program

Nafamostat mesilate

AF-0G-03-1.1-02

Approved small_molecule active

Quick answer

Nafamostat mesilate for Sepsis is a Approved program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Sepsis
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials